Risk of relapse after vedolizumab withdrawal in Inflammatory Bowel Disease for patients in histological remission

被引：0
|
作者：
Blad, W. [1 ]
Whitley, L. [1 ]
Harrow, P. [1 ]
机构：
[1] Univ Coll London Hosp, Dept Gastroenterol, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P808
引用
收藏
页码：942 / 942
页数：1
相关论文
共 50 条
  • [31] Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease
    Mahmoud, Remi
    Savelkoul, Edo H. J.
    Mares, Wout
    Goetgebuer, Rogier
    Witteman, Ben J. M.
    de Koning, Daan B.
    van Tuyl, Sebastiaan A. C.
    Minderhoud, Itta
    Lutgens, Maurice W. M. D.
    Akol-Simsek, Dilek
    van Schaik, Fiona D. M.
    Fidder, Herma H.
    Jansen, Jeroen M.
    van Boeckel, Petra G. A.
    Mahmmod, Nofel
    Horje, Carmen S. Horjus-Talabur
    Romkens, Tessa E. H.
    Colombel, Jean-Frederic
    Hoentjen, Frank
    Jharap, Bindia
    Oldenburg, Bas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (03) : 750 - +
  • [32] Vedolizumab Use in Pediatric Patients With Inflammatory Bowel Disease
    Singh, Namita
    Patel, Minesh
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2015, 148 (04) : S72 - S72
  • [33] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [34] Anti-TNF Withdrawal in Inflammatory Bowel Disease With Endoscopic Healing and the Risk of Relapse - Reply
    Mahmoud, Remi
    Savelkoul, Edo H. J.
    Jharap, Bindia
    Oldenburg, Bas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (07) : 1967 - 1968
  • [35] Vedolizumab Levels During Induction Are Associated With Remission in Patients With Inflammatory Bowel Diseases
    Yarur, Andres
    Bruss, Alexandra
    Patel, Amir
    Beniwal-Patel, Poonam
    Fox, Caroline
    Ungaro, Ryan
    Dubinsky, Marla C.
    Naik, Snehal
    Stein, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S353 - S354
  • [36] Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer
    Zenger, Cameron
    Hong, Simon J.
    Pecoriello, Jillian
    Pang, Alice S.
    Vallely, Margaret
    Hudesman, David
    Chang, Shannon
    Axelrad, Jordan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S460 - S460
  • [37] Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
    Pauwels, Renske W. M.
    van der Woude, Christien J.
    Erler, Nicole S.
    de Vries, Annemarie C.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [38] Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab
    Yamada, Akihiro
    Komaki, Yuga
    Patel, Nayan
    Komaki, Fukiko
    Aelvoet, Arthur S.
    Tran, Anthony L.
    Pekow, Joel
    Dalal, Sushila
    Cohen, Russell D.
    Cannon, Lisa
    Umanskiy, Konstantin
    Smith, Radhika
    Hurst, Roger
    Hyman, Neil
    Rubin, David T.
    Sakuraba, Atsushi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (09): : 1423 - 1429
  • [39] thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease
    Benitez, J. M.
    Garcia-Sanchez, V.
    Gisbert, J. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (05) : 494 - 495
  • [40] Reappraisal of Coronavirus Disease 2019 Risk for Patients With Inflammatory Bowel Disease: Withdrawal of the British Society of Gastroenterology Inflammatory Bowel Disease Risk Grid
    Ungaro, Ryan C.
    Kappelman, Michael D.
    GASTROENTEROLOGY, 2023, 164 (01) : 2 - 4
12345